Sientra, Inc.

122 articles about Sientra, Inc.

• Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

  2/13/2024

  Sientra, Inc. announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024.

• Sientra Reports Third Quarter Financial and Operational Results

  11/9/2023

  Sientra, Inc., a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced its financial results for the third quarter that ended September 30, 2023.

• Sientra to Present at the Stifel 2023 Healthcare Conference

  11/8/2023

  Sientra, Inc. today announced its participation at the  Stifel 2023 Healthcare Conference.

• Sientra Reports Record Second Quarter Financial and Operational Results

  8/10/2023

  Sientra, Inc., a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced its financial results for the second quarter that ended June 30, 2023.

• Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023

  7/27/2023

  Sientra, Inc., a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023.

• Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 30, 2023

  6/30/2023

  Sientra, Inc. announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees.

• Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

  6/20/2023

  Sientra, Inc. announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023.

• Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander

  6/8/2023

  Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510k-clearance for the Company’s novel, patented1 AlloX2 Pro Tissue Expander.

• Sientra Announces FDA-Clearance of Novel Portfinder™ Technology

  5/17/2023

  Sientra, Inc. announced that the Food and Drug Administration (FDA) has granted a 510(k) clearance for the Company’s novel Portfinder™ technology.

• Sientra Reports Record First Quarter 2023 Operational Results

  5/11/2023

  Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced its financial results for the first quarter that ended March 31, 2023.

• Sientra to Report First Quarter 2023 Financial Results on May 11, 2023

  5/1/2023

  Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023.

• Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction

  3/22/2023

  Aziyo Biologics, Inc. and Sientra, Inc. today announced they have entered into an agreement to expand the distribution of Aziyo’s SimpliDerm product line.

• Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

  3/20/2023

  Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Thursday, March 30, 2023.

• Sientra Announces Preliminary Results from Clinical Study and The First Shipment of Viality™ Fat Transfer SystemData Supports Enhanced Viability of Fat in Breast Augmentation and Reconstruction Using the Viality System

  3/1/2023

  Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that it has begun commercial shipping of its Viality™ with AuraClens™ fat transfer system.

• Sientra Announces 1-for-10 Reverse Stock Split

  1/20/2023

  Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s issued and outstanding common stock.

• Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 29, 2022

  12/29/2022

  Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that on December 27, 2022, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 13 new employees.

• SIENTRA ANNOUNCES LAUNCH OF VIALITY™, A NOVEL FAT TRANSFER SYSTEM

  12/5/2022

  Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery launched the Viality lipoaspirate wash system at the Beauty Through Science meeting in NYC this past Saturday.

• Sientra Reports Record Third Quarter 2022 Financial Results

  11/10/2022

  Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced its financial results for the third quarter that ended September 30, 2022.

• Sientra to Report Third Quarter 2022 Financial Results on November 10, 2022

  10/31/2022

  Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022.

• Sientra Announces Pricing of $13.2 Million Public Offering

  10/21/2022

  Sientra, Inc. today announced the pricing of its previously announced underwritten public offering of 34,782,600 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to an aggregate of 34,782,600 shares of common stock.